Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
To bolster its rare-diseases program, GlaxoSmithKline is teaming up with Montreal-based Angiochem to develop treatments for lysosomal storage diseases. Angiochem gets an up-front payment of as much as $31.5 million plus research funding it will use to develop enzyme replacement therapies (ERTs) that can cross the blood-brain barrier. Current ERTs are unable to address the neurological symptoms caused by lysosomal storage diseases. Angiochem’s engineered-peptide technology overcomes those limitations by binding to the LRP1 receptor, which provides a gateway into the brain.
This article has been sent to the following recipient: